{"entity":{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","aka":[],"tldr":"Hengrui's HER2 ADC, approved in China for lung cancer and showing Enhertu-scale results in breast cancer, part of a wave of Chinese ADCs heading for global trials.","summary":"NMPA approval May 2025 for HER2-mutant NSCLC (HORIZON-Lung: ORR 74.5%, PFS 11.5 months). HORIZON-Breast01 (HER2+ breast after trastuzumab/taxane): PFS 30.6 vs 8.3 months vs pyrotinib + capecitabine (HR 0.22). Also active in HER2-low breast cancer and as neoadjuvant therapy; global phase 1 (HORIZON-X) reported 2026. ILD ~3-5%.","status":"approved","asOf":"2026-09-07","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20rezetecan"}],"tags":[],"related":[],"cancers":["breast-her2-positive","nsclc"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":["her2"],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":["horizon-breast01","nct06199973","nct06828354","nct06430437","nct07196774","nct07676162","nct07051486","nct06840002","nct06859775","nct06222879","nct06015048","nct07497386","nct05814354","nct07102901","nct06057610","nct07111832","nct06778031","nct05482568","nct07110571","nct06126640","nct07679360","nct06413745","nct07140393","nct06123494","nct07231211","nct05671822"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"SHR-A1811","modality":"ADC","payload":"Rezetecan (SHR9265, camptothecin-derived TOP1 inhibitor), DAR ~6","linker":"Cleavable tetrapeptide","mechanism":"Trastuzumab-based antibody, cleavable linker, membrane-permeable TOP1 payload with bystander effect.","approvals":[{"region":"China","year":2025,"indication":"HER2-mutant NSCLC after ≥1 systemic therapy (May 2025)"}],"mechanismSteps":[],"dosing":{"route":"Intravenous","schedule":"4.8 mg/kg every 3 weeks (breast); 4.8-6.4 mg/kg studied"},"toxicity":[{"event":"Neutropenia","grade3PlusPct":40},{"event":"Nausea","anyGradePct":60},{"event":"Interstitial lung disease","anyGradePct":4}],"access":[],"regulatoryEvents":[{"date":"2025-05","type":"approval","region":"China","note":"HER2-mutant NSCLC","source":"https://www.precisionmedicineonline.com/precision-oncology/nmpa-approves-hengrui-pharmas-trastuzumab-rezetecan-her2-mutant-nsclc"}]},"route":"/drugs/trastuzumab-rezetecan/","neighbours":{"cancer":[{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/"},{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","route":"/companies/glenmark/"},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"trial":[{"id":"nct06840002","kind":"trial","name":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct06840002/"},{"id":"nct07676162","kind":"trial","name":"A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal","route":"/trials/nct07676162/"},{"id":"nct06778031","kind":"trial","name":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct06778031/"},{"id":"nct07111832","kind":"trial","name":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","route":"/trials/nct07111832/"},{"id":"nct07051486","kind":"trial","name":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer","route":"/trials/nct07051486/"},{"id":"nct06057610","kind":"trial","name":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct06057610/"},{"id":"nct06126640","kind":"trial","name":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","route":"/trials/nct06126640/"},{"id":"nct07140393","kind":"trial","name":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","route":"/trials/nct07140393/"},{"id":"nct07231211","kind":"trial","name":"A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors","route":"/trials/nct07231211/"},{"id":"nct06430437","kind":"trial","name":"A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations","route":"/trials/nct06430437/"},{"id":"nct06828354","kind":"trial","name":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","route":"/trials/nct06828354/"},{"id":"nct07679360","kind":"trial","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","route":"/trials/nct07679360/"},{"id":"nct07110571","kind":"trial","name":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","route":"/trials/nct07110571/"},{"id":"nct05482568","kind":"trial","name":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct05482568/"},{"id":"nct06015048","kind":"trial","name":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","route":"/trials/nct06015048/"},{"id":"nct07196774","kind":"trial","name":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","route":"/trials/nct07196774/"},{"id":"nct07497386","kind":"trial","name":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","route":"/trials/nct07497386/"},{"id":"nct07631884","kind":"trial","name":"Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","route":"/trials/nct07631884/"},{"id":"horizon-breast01","kind":"trial","name":"HORIZON-Breast01","route":"/trials/horizon-breast01/"},{"id":"nct06199973","kind":"trial","name":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, ","route":"/trials/nct06199973/"},{"id":"nct05671822","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","route":"/trials/nct05671822/"},{"id":"nct06413745","kind":"trial","name":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","route":"/trials/nct06413745/"},{"id":"nct07670273","kind":"trial","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","route":"/trials/nct07670273/"},{"id":"nct07704177","kind":"trial","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","route":"/trials/nct07704177/"},{"id":"nct05076682","kind":"trial","name":"Reverse Triple Negative Immune Resistant Breast Cancer","route":"/trials/nct05076682/"},{"id":"nct07102901","kind":"trial","name":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","route":"/trials/nct07102901/"},{"id":"nct06859775","kind":"trial","name":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06859775/"},{"id":"nct06123494","kind":"trial","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","route":"/trials/nct06123494/"},{"id":"nct05814354","kind":"trial","name":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","route":"/trials/nct05814354/"},{"id":"nct06222879","kind":"trial","name":"Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer","route":"/trials/nct06222879/"},{"id":"nct07129018","kind":"trial","name":"Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer","route":"/trials/nct07129018/"}],"person":[{"id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}